CSL Limited (CSLLY)
Healthcare · OQX · US
Price as at 1 Oct 2026, 17:28 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
CSL Limited trades at $31.01. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
Our moat model scores it 45 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
CSLLY dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $0.730 | 2 |
| 2025 | $0.325 | 1 |
| 2024 | $0.660 | 2 |
| 2023 | $0.590 | 2 |
| 2022 | $0.555 | 2 |
| 2021 | $0.555 | 2 |
| 2020 | $0.505 | 2 |
| 2019 | $0.463 | 2 |
| 2018 | $0.430 | 2 |
| 2017 | $0.340 | 2 |
| 2016 | $0.316 | 2 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
CSLLY earnings and analyst estimates
Recommendation mix, 1 published rating
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About CSL Limited
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
CSLLY passes 3 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Politician trades in CSLLY
Trades in CSLLY disclosed by members of Congress and executive-branch officials, latest first:
- Alan Armstrong · SenateBuy · $1,001 - $15,000 · traded 30 Mar 2026 · disclosed 21 Jul 2026
- Daniel Goldman · HouseSell · $50,001 - $100,000 · traded 10 Jul 2023 · disclosed 13 Aug 2023
- Daniel Goldman · HouseBuy · $15,001 - $50,000 · traded 27 Feb 2023 · disclosed 20 Mar 2023
- Greg Gianforte · HouseSell · $100,001 - $250,000 · traded 7 Dec 2018 · disclosed 29 Dec 2018
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
CSLLY peers
The largest companies in the same industry (Biotechnology), then in the same sector.
- RVMD Revolution Medicines, Inc.
- CMXHF CSL Limited
- ALNY Alnylam Pharmaceuticals, Inc.
- RPRX Royalty Pharma plc
- INCY Incyte Corporation
- INSM Insmed Incorporated
- GNMSF Genmab A/S
- JAZZ Jazz Pharmaceuticals plc
Every healthcare company we cover is on the Healthcare hub.
Common questions
Does CSL Limited (CSLLY) pay a dividend?
Yes. CSL Limited yields 2.27% at the current share price. It has paid $0.730 per share over the trailing twelve months. It has paid a dividend in each of the last 16 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
Where does SteadyShares get its CSLLY data?
Fundamentals for CSLLY come from company filings and exchange data, as listed on OQX; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 17:28 UTC and is delayed. Our data quality score for this company is 88/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for CSLLY, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.